Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.99
-$0.02(-4.12%)
At close: 4:00 PM EST
$3.99
-$0.02(-4.12%)
Day’s Range― - ―
52-Week Range$1.50 - $44.10
Previous CloseN/A
Volume102.01K
Average Volume (3M)115.06K
Market Cap
$6.12M
Enterprise Value$7.30
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 07, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.94
Shares Outstanding1,596,849
10 Day Avg. Volume42,648
30 Day Avg. Volume115,058
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside25.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.76
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue ReboundA sharp TTM revenue rebound with a ~97% gross margin indicates strong unit economics from recognized revenue streams or partnerships. Durable high gross margins provide fundamental leverage as programs scale, supporting longer-term margin expansion if operating expenses moderate or revenues grow.
Reclaimed Cell‑therapy License RightsRegaining exclusive rights to HCW9201/9206 lets the company directly capture future commercial or partnership value in CAR‑T/NK cell supply chains. This structurally improves optionality for licensing, collaborations or manufacturing deals and can accelerate monetization without royalty drag.
Positive Phase 1 Alopecia Clinical DataEarly Phase 1 efficacy and clean safety signals materially de‑risk the HCW9302 program and validate its Treg‑focused IL‑2 mechanism. This strengthens scientific credibility, supports dose selection plans and increases attractiveness to partners or funders for broader autoimmune development.
Bears Say
Persistent Cash Burn & Negative FCFSustained ~-$11.5M operating and free cash flow reflects a heavy cash burn profile that will require recurring external funding. Over 2–6 months this constrains strategic flexibility, risks dilutive financings, and limits the company’s ability to self‑fund multiple clinical programs concurrently.
Ongoing Nasdaq Monitoring And Listing RiskExtended Nasdaq monitoring and prior need for reverse splits create a persistent governance and compliance overhang. This structural listing risk can force corporate actions (reverse splits, capital raises) and deter long‑term institutional investors, affecting access to stable capital.
Reliance On Dilutive Financings And ApprovalsRecent private placements, authorized warrants and repeat shareholder votes signal ongoing dependence on equity and warrant financing. This creates a structural dilution risk and recurring governance burdens that can reduce shareholder value and complicate long‑term capital planning.
HCW Biologics News
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $1.50 and its highest was $44.10 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $6.12M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 16 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on May 14, 2026. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Undervalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate is -1.98.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 1,596,849 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of $0.37 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 262.018%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(25.31% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
54.89% Insiders
1.55% Mutual Funds
― Other Institutional Investors
43.43% Public Companies and
Individual Investors